Quercetin in Children With Fanconi Anemia; a Pilot Study

• Status: Recruiting
• Trial end date: 2023-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Fanconi anemia (FA) is an autosomal recessive disease characterized by progressive bone marrow failure (BMF), congenital abnormalities and a predisposition to malignancy.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Children's Hospital Medical Center, Cincinnati
• Collaborator: Food and Drug Administration (FDA)
• Treatments: Quercetin

Criteria

Inclusion Criteria:

• Diagnosis of FA proven by DEB test or molecular testing

• Able to take enteral medication

• All age groups, including adults

Exclusion Criteria:

• Patients with morphological evidence of myelodysplasia or leukemia

• Renal failure requiring dialysis

• Total bilirubin > 3 mg/dl and/or SGPT >200 at time of enrollment

• Patients who are pregnant or breastfeeding or are at risk of pregnancy and are unable to use acceptable methods of birth control during the length of the study

• Patients receiving cyclosporine or digoxin therapy or are unable to discontinue either treatment due to medical reasons

• Patients who have received quercetin supplementation or other antioxidants within the last 30 days